ArticleDiagnostic cytopathology2026
Analysis of SWI Complex Subunits in 69 Cases of TTF-1 Negative Non-Small Cell Lung Carcinoma.
Article in Diagnostic cytopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Non-small cell lung carcinomas, not otherwise specified (NSCLC-NOS) with a specific signature including high-grade hepatoid/clear cell morphology, negative lung panel mutational analysis, negative TTF-1/Napsin A staining can be reported as a morphologic variant of an aggressive carcinoma with loss of one of the subunits of the SWI/SNF-chromatin complex. However, this entity is often underdiagnosed, and the specific percentages of each subunit affected remain unclear. In this study, we used immunomarkers for common major (BRG1 and BRM) and minor subunits (ARID1B, ARID1B, and ARID2) in suspicious cases in a retrospective method. Our study revealed that 90% (62 out of 69 cases) of the cases exhibiting the abovementioned signature showed loss of one of the common SWI/SNF complex subunits, with BRG1 and ARID1B being the most lost subunits. We suggest that the combination of hepatoid or clear cell cytomorphology, negative TTF1/Napsin A, and negative lung panel mutational analysis should trigger immunohistochemical examination of SWI subunits expression. The uniqueness of this study lies in the large number of cases, with their specimens obtained via cytopathological methods and immunostained with all five common SWI markers. This study contributes to the familiarity and awareness of pathologists and oncologists by highlighting the importance of cytomorphology and immunohistochemical profile of SWI/SNF-deficient NSCLC-NOS, facilitating earlier diagnosis, and may ultimately lead to more specific and novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.